[HTML][HTML] Drug combination therapy for emerging viral diseases
ZA Shyr, YS Cheng, DC Lo, W Zheng - Drug discovery today, 2021 - Elsevier
Effective therapeutics to combat emerging viral infections are an unmet need. Historically,
treatments for chronic viral infections with single drugs have not been successful, as …
treatments for chronic viral infections with single drugs have not been successful, as …
[HTML][HTML] Treatment of liver fibrosis: Past, current, and future
Liver fibrosis accompanies the progression of chronic liver diseases independent of
etiologies, such as hepatitis viral infection, alcohol consumption, and metabolic-associated …
etiologies, such as hepatitis viral infection, alcohol consumption, and metabolic-associated …
The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting
GG Naguib, TG Michael, Y Elshazly, MM Wahdan… - VirusDisease, 2021 - Springer
The aim of this study was to compare efficacy and safety of different combination regimens in
re-treatment of HCV in the setting of inaccessibility of resistance testing. This real-life …
re-treatment of HCV in the setting of inaccessibility of resistance testing. This real-life …
Efficacy and safety of ombitasvir plus paritaprevir, ritonavir and ribavirin in non-cirrhotic treatment-naïve and treatment-experienced egyptians with chronic HCV …
Hepatitis C virus genotype 4 (HCV-GT4) is a risk factor for cirrhosis, hepatocellular
carcinoma and liver failure. A combination of three new direct-acting antivirals ombitasvir …
carcinoma and liver failure. A combination of three new direct-acting antivirals ombitasvir …
Quadruple therapy offers high SVR rates in patients with HCV genotype 4 with previous treatment failure
YEE Abo-Amer, R Badawi, M El-Abgeegy… - Advances in …, 2020 - Wiley Online Library
Background and Aims. Direct‐acting antivirals (DAAs) have made a revolution in hepatitis C
virus (HCV) treatment with promising reduction of HCV infection and disease morbidities …
virus (HCV) treatment with promising reduction of HCV infection and disease morbidities …
Comparative Real Life Egyptian Experience of the Combination of Sofosbuvir Plus Daclatasvir or Simeprevir for 12 Weeks in Naïve Cirrhotic Patients Infected with …
S Ahmed, E Hassan, A Gomaa, G Esamat… - Current Drug …, 2023 - ingentaconnect.com
Background: Chronic infection with HCV is progressive worldwide health problem and the
core reason for liver cirrhosis, portal hypertension, or hepatocellular carcinoma. HCV-G4 …
core reason for liver cirrhosis, portal hypertension, or hepatocellular carcinoma. HCV-G4 …
Establishing a research production line in real-life settings: the case of Hepatitis C management in a viral hepatitis specialized Egyptian center
M El Kassas, M Eltabbakh, M Elbadry… - Current Medical …, 2022 - Taylor & Francis
Efforts toward eradicating the Hepatitis C virus (HCV) have advanced rapidly, due to the
development of direct-acting antivirals (DAAs), especially with the appearance of pan …
development of direct-acting antivirals (DAAs), especially with the appearance of pan …
[HTML][HTML] Assessment of efficacy and safety of two Egyptian protocols for treatment-experienced HCV patients: an observational study
RS Hagag, MM Fakhry, OA Ahmed… - The Egyptian Journal of …, 2022 - Springer
Background The devastating adverse effects of interferon (IFN) for the treatment of hepatitis
C virus (HCV) lead to the emerging of direct acting antiviral agents (DAAs). This …
C virus (HCV) lead to the emerging of direct acting antiviral agents (DAAs). This …
[PDF][PDF] Comparative Real Life Egyptian Experience of the Combination of Sofos-buvir Plus Daclatasvir or Simeprevir for 12 Weeks in Naïve Cirrhotic Pa-tients Infected …
EH Sayed Ahmed, A Gomaa, G Esamat, A Ramadan… - researchgate.net
Background: Chronic infection with HCV is progressive worldwide health problem and the
core reason for liver cirrhosis, portal hypertension, or hepatocellular carcinoma. HCV-G4 …
core reason for liver cirrhosis, portal hypertension, or hepatocellular carcinoma. HCV-G4 …